

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ab&B Bio-Tech CO., LTD. JS

江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

VOLUNTARY ANNOUNCEMENT

APPROVAL OF OUR APPLICATION FOR TRIVALENT SUBUNIT INFLUENZA VACCINE BY THE NMPA

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the “**Company**” or “**Ab&B Bio-Tech**”, together with its subsidiary, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, the National Medical Products Administration of the People's Republic of China (the “**NMPA**”) has approved the new drug application for the Group's trivalent subunit influenza vaccine for all age groups.

This was the first and only trivalent subunit influenza vaccine approved in China for all age groups at full dosage level as of the date of this announcement. This product is a significant upgrade from the traditional split-virion vaccines, offering comprehensive protection, high antigen purity and low risks of adverse reactions.

About Ab&B Bio-Tech

Ab&B Bio-Tech is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. In formulating our pipeline, we closely track global trends in infectious disease incidence and vaccine R&D, with a strategic focus on premium vaccines, aiming to replace traditional vaccines and imported vaccines in China and establish our presence in international markets. Our range of products include but are not limited to, the trivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with other vaccine candidates.

This announcement is published on a voluntary basis by the Company. There is no assurance that the Group will be able to ultimately develop and market its trivalent subunit influenza vaccine, for all intended age groups successfully. **Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai

Executive Director, chairman of our Board and general manager

Hong Kong, January 30, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun and Mr. CHEN Chengbei as independent non-executive Directors.